Niagen Bioscience, Inc. current report, 04 April 2022

Business Context and Reporting Period

This Form 8-K is a current report filed by ChromaDex Corporation (CDXC) on April 8, 2022, regarding an event that occurred on April 4, 2022. The filing addresses a change in the composition of the Board of Directors.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and contains no financial performance data.

Material Changes

On April 4, 2022, Jeffery Baxter resigned from the Board of Directors, effective immediately. Consequently, he also stepped down from his roles as a member of the Audit Committee and the Nominating and Corporate Governance Committee.

Management Commentary and Risks

Mr. Baxter indicated that his resignation is not due to any disagreement with the Company on any matter relating to its operations, policies, or practices. No other risks, contingencies, or unusual items were disclosed in this filing.

Investor Verification Checklist

  • Verify the current composition of the Board of Directors following Mr. Baxter's departure.
  • Confirm whether a replacement director has been appointed to fill the vacancy.
  • Review the status of the Audit Committee and Nominating and Corporate Governance Committee to ensure quorum and compliance.